BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $116.6 million versus the consensus estimate of $119.24 million.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Greenlight Captial Re (GLRE) Misses Q2 EPS by 40c
- ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
